Leveraging Viruses for the Treatment of Viral Diseases and Cancer: Improving Host Fitness by Combinations of Virus and Host Genes gives a comprehensive overview on the impact of using naturally or intentionally attenuated viruses - which are apathogenic to people - to control viral diseases and cancer. It examines the potential of exploiting, developing, and using apathogenic viruses as therapeutic tools. Sections cover the COVID-19 pandemic and the need for a post-Infection Plan B to combat SARS-CoV-2 infections as gaps in testing and vaccination create the perfect conditions for a new variant of concern to emerge.
More generally, the book also provides specific examples of the use of apathogenic viruses to treat other infectious diseases. It discusses the process of manufacturing viral therapies and how infectious disease treatments can be repurposed to improve other therapies like for cancer. With contribution from an international group of contributors, Leveraging Viruses for the Treatment of Viral Diseases and Cancer is useful references for those engages in study and development of infectious diseases and ways to combat them.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iv 6. Dedication - p. v 7. List of contributors - p. xi 8. About the editor - p. xiii 9. Preface - p. xv 10. Chapter 1. Rethinking viruses: beyond the pathogen paradigm in virome-host interactions - p. 1 11. Chapter 2. Animal industries and zoonotic disease in the United States - p. 17 12. Chapter 3. Natural and artificial viral interference in viral diseases - p. 39 13. Chapter 4. Using nonpathogenic picornaviruses to combat emerging viral infections - p. 59 14. Chapter 5. Vaccinology: time to change paradigm? Beneficial nonspecific effects of live vaccines against unrelated infections - p. 69 15. Chapter 6. Postinfection viral therapy to complement vaccinations against known and emerging viruses - p. 87 16. Chapter 7. Acyclovir with add-on immunostimulatory IBDV substantially reduces the crusting time of shingles - p. 99 17. Chapter 8. Combination of infectious bursal disease virus with ultra-low doses of nivolumab plus ipilimumab could provide functional cure in chronic hepatitis B virus infections - p. 115 18. Chapter 9. Breakthrough infection in the presence of neutralizing antibodies by repeated oral administration of viruses - p. 139 19. Chapter 10. Infectious bursal disease virus is easy to manufacture and affordable - p. 151 20. Chapter 11. Turning self cancer cells into nonself by viral xenogenization to ignite response in immune checkpoint inhibitors nonresponders - p. 163 21. Index - p. 189
Leveraging Viruses for the Treatment of Viral Diseases and Cancer: Improving Host Fitness by Combinations of Virus and Host Genes gives a comprehensive overview on the impact of using naturally or intentionally attenuated viruses - which are apathogenic to people - to control viral diseases and cancer. It examines the potential of exploiting, developing, and using apathogenic viruses as therapeutic tools. Sections cover the COVID-19 pandemic and the need for a post-Infection Plan B to combat SARS-CoV-2 infections as gaps in testing and vaccination create the perfect conditions for a new variant of concern to emerge.
More generally, the book also provides specific examples of the use of apathogenic viruses to treat other infectious diseases. It discusses the process of manufacturing viral therapies and how infectious disease treatments can be repurposed to improve other therapies like for cancer. With contribution from an international group of contributors, Leveraging Viruses for the Treatment of Viral Diseases and Cancer is useful references for those engages in study and development of infectious diseases and ways to combat them.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iv 6. Dedication - p. v 7. List of contributors - p. xi 8. About the editor - p. xiii 9. Preface - p. xv 10. Chapter 1. Rethinking viruses: beyond the pathogen paradigm in virome-host interactions - p. 1 11. Chapter 2. Animal industries and zoonotic disease in the United States - p. 17 12. Chapter 3. Natural and artificial viral interference in viral diseases - p. 39 13. Chapter 4. Using nonpathogenic picornaviruses to combat emerging viral infections - p. 59 14. Chapter 5. Vaccinology: time to change paradigm? Beneficial nonspecific effects of live vaccines against unrelated infections - p. 69 15. Chapter 6. Postinfection viral therapy to complement vaccinations against known and emerging viruses - p. 87 16. Chapter 7. Acyclovir with add-on immunostimulatory IBDV substantially reduces the crusting time of shingles - p. 99 17. Chapter 8. Combination of infectious bursal disease virus with ultra-low doses of nivolumab plus ipilimumab could provide functional cure in chronic hepatitis B virus infections - p. 115 18. Chapter 9. Breakthrough infection in the presence of neutralizing antibodies by repeated oral administration of viruses - p. 139 19. Chapter 10. Infectious bursal disease virus is easy to manufacture and affordable - p. 151 20. Chapter 11. Turning self cancer cells into nonself by viral xenogenization to ignite response in immune checkpoint inhibitors nonresponders - p. 163 21. Index - p. 189
